Skip to main content
See every side of every news story
Get Started
SubscribeLogin
Published • loading... • Updated

Chardan Capital Reaffirms "Buy" Rating for Palvella Therapeutics (NASDAQ:PVLA)

Summary by MarketBeat
Chardan Capital reissued a "buy" rating and issued a $240.00 price target on shares of Palvella Therapeutics in a research note on Wednesday.

1 Articles

MarketBeatMarketBeat
Center

Chardan Capital Reaffirms "Buy" Rating for Palvella Therapeutics (NASDAQ:PVLA)

Chardan Capital reissued a "buy" rating and issued a $240.00 price target on shares of Palvella Therapeutics in a research note on Wednesday.

·Sioux Falls, United States
Read Full Article
Think freely.Subscribe and get full access to Ground NewsSubscriptions start at $9.99/yearSubscribe

Bias Distribution

  • 100% of the sources are Center
100% Center

Factuality Info Icon

To view factuality data please Upgrade to Premium

Ownership

Info Icon

To view ownership data please Upgrade to Vantage

MarketBeat broke the news in Sioux Falls, United States on Wednesday, October 28, 2026.
Too Big Arrow Icon
Sources are mostly out of (0)
Blindspot Title And Logo
Stories disproportionately reported by the Left or the Right

Similar News Topics

Wayne, Pennsylvania icon

Wayne, Pennsylvania

News
Feed Dots Icon
For You
Search Icon
SearchBlindspot LogoBlindspotLocal